Trial compared Enhertu with T-DM1 in patients with HER2-positive breast cancer More: Enhertu improves progression-free survival in breast cancer trial Source: News
read moreThe enzyme replacement therapy is designed to target the key mannose-6-phosphate receptor pathway More: US approval for Sanofi’s late-onset Pompe disease med Nexviazyme Source: News
read moreHigh levels of skin clearance achieved for moderate to severe plaque psoriasis patients More: Interim trial data for UCB’s bimekizumab shows positive results Source: News
read moreApproval based on DAPA-CKD Phase III data More: AZ’s Forxiga gains EC, MHRA approvals for chronic kidney disease Source: News
read moreSanofi notches another Pompe win with FDA blessing for enzyme replacement therapy Nexviazyme fkansteiner Fri, 08/06/2021 – 14:44 More: Sanofi notches another Pompe win with FDA blessing for enzyme replacement therapy Nexviazyme Source: fierce
read moreFrom vaccine halo to liability? Reputation tracker says COVID-19 shot makers now dinged for safety, supply issues bbulik Fri, 08/06/2021 – 14:24 More: From vaccine halo to liability? Reputation tracker says COVID-19 shot makers now dinged for safety, supply issues
read more© 1994 - 2026 B.M. Pharmaceuticals